Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 5.93B |
| Revenue (ttm) | 787.65M |
| Net Income (ttm) | -366.29M |
| Shares Out | 145.75M |
| EPS (ttm) | -2.56 |
| PE Ratio | n/a |
| Forward PE | 90.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 846,040 |
| Open | 40.88 |
| Previous Close | 40.81 |
| Day's Range | 40.39 - 41.23 |
| 52-Week Range | 34.32 - 54.44 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 58.00 (+42.58%) |
| Earnings Date | May 1, 2024 |
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen ... [Read more]
Financial Performance
In 2023, IONS's revenue was $787.65 million, an increase of 34.10% compared to the previous year's $587.37 million. Losses were -$366.29 million, 35.8% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is $58.0, which is an increase of 42.58% from the latest price.
News
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – ...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. , April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 23...
Ionis to hold olezarsen Phase 3 data webcast
Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif.
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
– First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute pancreatitis events in patients with rare, life-threatening disease, for whic...
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of a mid-stage trial.
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Significant improvement in steatohepatitis with > 2 point improvement in NAS score without worsening fibrosis, the primary endpoint of the study Achieved key secondary endpoint of MASH resolution with...
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Kyle Jenne rejoins company to lead commercial strategy Onaiza Cadoret-Manier departing for new career opportunity With broad commercial capabilities in place, Ionis ready to execute on its first inde...
Ionis reports fourth quarter and full year 2023 financial results
WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, resp...
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the ...
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis ...
Ionis to hold fourth quarter and full year 2023 financial results webcast
Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
MARSEILLE, France--(BUSINESS WIRE)--Vect-Horus announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).
Ionis Pharma's genetic disease drug succeeds in late-stage study
Ionis Pharmaceuticals said on Monday its therapy for the treatment of a rare genetic disease met the main goal in a late-stage trial.
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks Donidalorsen demonstrat...
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif. , Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlig...
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and ...
US FDA approves Ionis-AstraZeneca's nerve disease drug
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 20, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients Ionis plans to independently bring donidalorsen to U.S. patients if approved Donidalorsen...
Ionis announces the appointment of Michael Yang to Board of Directors
CARLSBAD, Calif. , Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Bo...
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part ...
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Continued treatment over two years with donidalorsen demonstrated sustained reduction in hereditary angioedema attacks and improved quality of life Donidalorsen recently received orphan drug designati...
Ionis reports third quarter 2023 financial results
Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients with FCS; on track for regulator...
Ionis to hold third quarter 2023 financial results webcast
Webcast scheduled for Thursday, November 2 at 11:30 a.m. Eastern Time CARLSBAD, Calif.